Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944372 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors
A Phase 4 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00944372 is a Phase 4 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 150 participants.
The verdict
NCT00944372, a Phase 4 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the effect of age (geriatric) and renal function on the safety, efficacy and pharmacokinetics of OctreoScan at the recommended clinical dose in this patient population.
Interventions
- DRUG Indium In-111 pentetreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00944372
The ClinicalTrials.gov registry entry for NCT00944372 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Indium In-111 pentetreotide is the first listed.
NCT00944372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00944372 about?
NCT00944372 is a clinical study titled "Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors". The objective of this study was to evaluate the effect of age (geriatric) and renal function on the safety, efficacy and pharmacokinetics of OctreoScan at the recommended clinical dose in this patient population.
What is the current status of trial NCT00944372?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2003-07. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00944372?
The interventions under investigation include: Indium In-111 pentetreotide (DRUG).
Who is sponsoring clinical trial NCT00944372?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.